DeepMed Research

argenx

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Established: 2008-01-01

Employees: -

Market Cap: $31.2B

Website: https://www.argenx.com/

Clinical Trials

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

Phase 2

Completed

Conditions: Primary Sjögren's Syndrome

Interventions: Biological: Efgartigimod

First Posted Date: 2024-01-12

Last Posted Date: 2025-04-03

Lead Sponsor: argenx

Target Recruit Count: 24

Registration Number: NCT06203457

Locations: 🇭🇺
Debreceni Egyetem, Debrecen, Hungary
🇵🇱
Centrum Medyczne Pratia Poznan, Skorzewo, Poland
🇵🇱
FutureMeds sp zoo, Wroclaw, Poland

and more 8 locations

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

Recruiting

Conditions: Congenital Myasthenic Syndrome

First Posted Date: 2023-10-12

Last Posted Date: 2025-05-11

Lead Sponsor: argenx

Target Recruit Count: 100

Registration Number: NCT06078553

Locations: 🇨🇦
The Ottawa Hospital - Civic Campus, Ottawa, Canada
🇫🇷
CHU Timone, Marseille, France
🇫🇷
Assistance Publique Hopitaux de Paris - Hopital Pitie-Salpetriere, Paris, France

and more 7 locations

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

Active, not recruiting

Conditions: Multifocal Motor Neuropathy

First Posted Date: 2023-08-14

Last Posted Date: 2025-02-07

Lead Sponsor: argenx

Target Recruit Count: 413

Registration Number: NCT05988073

Locations: 🇩🇪
Universitatsklinikum Wurzburg, Wurzburg, Germany
🇮🇹
Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
🇮🇹
Fondazione Serena Onlus - NeMO Brescia, Gussago, Italy

and more 110 locations

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

Phase 3

Conditions: Myositis
Polymyositis
Dermatomyositis
Immune-Mediated Necrotizing Myopathy
Antisynthetase Syndrome
Active Idiopathic Inflammatory Myopathy

Interventions: Biological: EFG PH20 SC

First Posted Date: 2023-08-07

Last Posted Date: 2025-05-22

Lead Sponsor: argenx

Target Recruit Count: 240

Registration Number: NCT05979441

Locations: 🇧🇬
Medical Centre Artmed, Plovdiv, Bulgaria
🇨🇾
Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
🇨🇿
Revmatologicky Ustav, Praha, Czechia

and more 48 locations

A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Biological: Efgartigimod IV

First Posted Date: 2023-07-03

Last Posted Date: 2024-06-26

Lead Sponsor: argenx

Target Recruit Count: 33

Registration Number: NCT05927415

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪
APEX GmbH, Munich, Germany

Open Label Extension of Efgartigimod in Adults with Post-COVID-19 POTS

Phase 2

Terminated

Conditions: Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

Interventions: Drug: Efgartigimod

First Posted Date: 2023-06-26

Last Posted Date: 2024-12-04

Lead Sponsor: argenx

Target Recruit Count: 33

Registration Number: NCT05918978

Locations: 🇺🇸
North Shore University HealthSystem, Glenview, Illinois, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 6 locations

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

Phase 2

Recruiting

Conditions: Delayed Graft Function

Interventions: Biological: ARGX-117
Other: Placebo

First Posted Date: 2023-06-18

Last Posted Date: 2025-04-01

Lead Sponsor: argenx

Target Recruit Count: 102

Registration Number: NCT05907096

Locations: 🇪🇸
Hospital Universitario Miguel Servet, Zaragoza, Spain
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Columbia University, New York, New York, United States

and more 42 locations

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Biological: efgartigimod PH20 SC as a prefilled syringe presentation
Biological: efgartigimod PH20 SC as a vial + syringe presentation

First Posted Date: 2023-04-18

Last Posted Date: 2023-10-31

Lead Sponsor: argenx

Target Recruit Count: 120

Registration Number: NCT05817435

Locations: 🇺🇸
Investigator site 0010209, Tempe, Arizona, United States
🇺🇸
Investigator site 0010208, Lincoln, Nebraska, United States

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

Phase 2

Completed

Conditions: Primary Sjögren's Syndrome

Interventions: Biological: Placebo
Biological: Efgartigimod

First Posted Date: 2023-04-18

Last Posted Date: 2024-05-28

Lead Sponsor: argenx

Target Recruit Count: 34

Registration Number: NCT05817669

Locations: 🇵🇱
ETG Lublin, Lublin, Poland
🇵🇱
Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k., Poznan, Poland
🇵🇱
MICS Centrum Medyczne Warszawa, Warszawa, Poland

and more 14 locations

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

Phase 2

Terminated

Conditions: Membranous Nephropathy

Interventions: Other: placebo
Biological: efgartigimod IV

First Posted Date: 2023-04-13

Last Posted Date: 2024-11-22

Lead Sponsor: argenx

Target Recruit Count: 8

Registration Number: NCT05810961

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fujian, China
🇨🇳
Fuyang People's Hospital, Fuyang, China
🇨🇳
Peking University People's Hospital, Beijing, China

and more 28 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy